A Randomised, Double Blind (Sponsor Unblinded), Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis

Trial Profile

A Randomised, Double Blind (Sponsor Unblinded), Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Subjects and Patients With Plaque Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs GSK 2831781 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Jul 2017 Planned End Date changed from 3 Jun 2018 to 15 Aug 2018.
    • 24 Jul 2017 Planned primary completion date changed from 3 Jun 2018 to 15 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top